1. A 29-year-old man with treatment-resistant schizophrenia was started on clozapine 5 weeks ago and titrated to 300 mg per day. He presents with a 3-day history of fatigue, low-grade fever, pleuritic chest pain, and exertional dyspnea. Vital signs show heart rate 118 beats per minute and temperature 38.1°C. Laboratory testing reveals an elevated troponin, elevated C-reactive protein (CRP), and a normal absolute neutrophil count. An electrocardiogram shows sinus tachycardia with nonspecific ST-T changes. Which clozapine-associated adverse effect best explains this presentation, and what is the appropriate immediate action?
A) Clozapine-induced agranulocytosis; the immediate action is to obtain a repeat absolute neutrophil count and withhold clozapine pending the result
B) Clozapine-induced myocarditis, which characteristically occurs within the first 6 to 8 weeks of treatment; the immediate action is to discontinue clozapine and obtain urgent cardiology evaluation including echocardiography
C) Clozapine-induced seizure activity; the immediate action is to add a prophylactic antiepileptic agent and continue clozapine
D) Clozapine-induced metabolic syndrome with hyperglycemia; the immediate action is to start metformin and continue clozapine
E) Clozapine-induced sialorrhea with aspiration pneumonia; the immediate action is to add an anticholinergic agent and continue clozapine
ANSWER: B
Rationale:
This presentation — fever, chest pain, dyspnea, tachycardia, elevated troponin and CRP within the first 6 to 8 weeks of clozapine initiation — is the classic picture of clozapine-induced myocarditis. Myocarditis and cardiomyopathy are rare but serious cardiac adverse effects reported predominantly in the first 6 to 8 weeks; some guidelines recommend baseline and serial troponin and CRP monitoring during the initiation period for this reason. The appropriate immediate action is to discontinue clozapine and obtain urgent cardiology evaluation, including echocardiography to assess ventricular function. Continuing clozapine in the face of suspected myocarditis risks progression to cardiomyopathy and death.
Option A: Option A is incorrect because the absolute neutrophil count is explicitly normal in this patient; the clinical picture is cardiac, not hematologic, and agranulocytosis does not explain troponin elevation or chest pain.
Option C: Option C is incorrect because seizures do not produce fever, troponin elevation, and pleuritic chest pain; moreover, the correct response to suspected myocarditis is discontinuation, not continuation with an added agent.
Option D: Option D is incorrect because metabolic syndrome and hyperglycemia do not cause acute troponin elevation, fever, and pleuritic chest pain; this is not a metabolic presentation, and continuing clozapine would be unsafe.
Option E: Option E is incorrect because sialorrhea with aspiration pneumonia would not typically produce troponin elevation, and the temporal pattern and cardiac biomarkers point to myocarditis; continuing clozapine would be inappropriate.
2. A 41-year-old woman has been stable on clozapine 400 mg per day for 4 months for treatment-resistant schizophrenia. Her routine Clozapine REMS absolute neutrophil count (ANC), drawn as part of mandatory monitoring, returns at 900 cells per microliter. She has no fever, no signs of infection, and is not of an ancestry associated with benign ethnic neutropenia. According to the REMS monitoring framework, what is the appropriate management of her clozapine at this ANC?
A) The ANC of 900 cells per microliter falls in the moderate-to-severe neutropenia range (below 1000 cells per microliter); clozapine should be interrupted, hematology should be involved, and ANC should be monitored closely to determine whether the count recovers or continues to fall
B) The ANC of 900 cells per microliter is within normal limits; no change to clozapine or monitoring frequency is required
C) The ANC of 900 cells per microliter meets the definition of agranulocytosis; clozapine should be permanently discontinued and the patient placed on the non-rechallenge list immediately
D) The ANC of 900 cells per microliter requires only an increase in monitoring frequency to weekly, with no interruption of clozapine
E) The ANC of 900 cells per microliter should prompt an immediate clozapine dose increase to overcome presumed laboratory error
ANSWER: A
Rationale:
An ANC of 900 cells per microliter falls below the 1000 cells per microliter threshold that defines moderate-to-severe neutropenia in the Clozapine REMS framework. At this level, clozapine should be interrupted, hematology should be consulted, and the ANC should be monitored closely to determine the trajectory. This is distinct from agranulocytosis (ANC below 500), which mandates permanent discontinuation and non-rechallenge listing. The correct action here is interruption with close monitoring, not permanent discontinuation, because the count has not yet reached the agranulocytosis threshold and may recover.
Option B: Option B is incorrect because 900 cells per microliter is not within normal limits; it is below the moderate-to-severe neutropenia threshold and requires action under the REMS protocol.
Option C: Option C is incorrect because agranulocytosis is defined as an ANC below 500 cells per microliter, not 900; permanent discontinuation and non-rechallenge listing are not yet warranted at this count, which calls for interruption and monitoring.
Option D: Option D is incorrect because an ANC of 900 cells per microliter requires clozapine interruption, not merely a monitoring-frequency increase; continuing clozapine at this neutrophil count would be unsafe.
Option E: Option E is incorrect because a dose increase in the face of neutropenia is dangerous and pharmacologically nonsensical; agranulocytosis is idiosyncratic and not overcome by dose escalation, and the appropriate response to a low ANC is interruption, not escalation.
3. A 36-year-old man with treatment-resistant schizophrenia and comorbid obsessive-compulsive disorder is stable on clozapine 350 mg per day. His psychiatrist adds fluvoxamine 100 mg per day to target the obsessive-compulsive symptoms. Over the following 10 days, he becomes markedly sedated, develops hypersalivation that soaks his pillow at night, and has an episode of near-syncope on standing. He is afebrile with a normal absolute neutrophil count. Which mechanism best explains this clinical deterioration, and what is the most appropriate management?
A) Fluvoxamine has displaced clozapine from plasma protein binding sites; the appropriate management is to increase the clozapine dose to compensate for accelerated clearance
B) Fluvoxamine has induced CYP1A2, lowering clozapine levels and causing withdrawal symptoms; the appropriate management is to increase the clozapine dose
C) The symptoms represent an unrelated viral illness; the appropriate management is to continue both medications unchanged and provide supportive care
D) Fluvoxamine, a potent CYP1A2 inhibitor, has substantially raised clozapine plasma levels (potentially 5- to 10-fold), producing dose-related toxicity (sedation, sialorrhea, orthostasis); the appropriate management is to reduce the clozapine dose with plasma-level monitoring, or reconsider the combination
E) Fluvoxamine has triggered clozapine-induced agranulocytosis; the appropriate management is to discontinue clozapine permanently and check the absolute neutrophil count
ANSWER: D
Rationale:
Clozapine is cleared approximately 70 to 80% by CYP1A2. Fluvoxamine is a potent CYP1A2 inhibitor and can raise clozapine plasma levels 5- to 10-fold. The patient's sedation, hypersalivation (sialorrhea), and orthostatic near-syncope are manifestations of dose-related clozapine toxicity from the markedly elevated plasma level. The appropriate management is to reduce the clozapine dose with therapeutic drug monitoring — or reconsider the combination. Although the fluvoxamine-clozapine interaction can be exploited deliberately to allow a lower clozapine dose, doing so requires anticipatory dose reduction and monitoring; here the dose was not reduced when fluvoxamine was added, producing toxicity.
Option A: Option A is incorrect because the mechanism is CYP1A2 enzyme inhibition (reduced metabolism, higher levels), not protein-binding displacement, and increasing the dose would worsen the toxicity.
Option B: Option B inverts the pharmacology: fluvoxamine inhibits CYP1A2 and raises clozapine levels; it does not induce the enzyme or cause withdrawal, and a dose increase would be dangerous.
Option C: Option C is incorrect because the temporal association with fluvoxamine initiation and the specific constellation of clozapine toxicity signs make a coincidental viral illness an unsafe assumption; continuing both drugs unchanged risks worsening toxicity.
Option E: Option E is incorrect because the absolute neutrophil count is normal and the symptoms are those of dose-related clozapine toxicity, not agranulocytosis; fluvoxamine does not trigger agranulocytosis, which is idiosyncratic and not interaction-driven.
4. A 33-year-old man with schizophrenia, on olanzapine 20 mg per day for 9 months with no prior diabetes history, is brought to the emergency department with a 2-day history of polyuria, polydipsia, nausea, and progressive lethargy. Laboratory testing reveals a plasma glucose of 480 mg/dL, an anion-gap metabolic acidosis, positive serum ketones, and a bicarbonate of 12 mEq/L. Which statement best characterizes this presentation and the appropriate approach?
A) This is an expected and benign consequence of olanzapine therapy that requires no acute intervention beyond reassurance
B) This presentation is unrelated to olanzapine because antipsychotics do not affect glucose metabolism; the workup should focus exclusively on type 1 diabetes
C) This is diabetic ketoacidosis (DKA), a recognized metabolic emergency that can occur with olanzapine even without prior diabetes; management requires emergent treatment of the DKA (intravenous fluids, insulin, electrolyte correction) and reassessment of the antipsychotic, with strong consideration of switching to a metabolically favorable agent once the patient is stabilized
D) This presentation indicates clozapine-level toxicity and should be managed by checking a clozapine plasma level
E) This is olanzapine-induced agranulocytosis presenting atypically; the priority is an urgent absolute neutrophil count
ANSWER: C
Rationale:
This is diabetic ketoacidosis — hyperglycemia, anion-gap metabolic acidosis, and ketosis — occurring in a patient on olanzapine without prior diabetes. Olanzapine carries one of the highest risks of glucose dysregulation in the antipsychotic class, and cases of new-onset DKA have been reported in patients on olanzapine without a prior diabetes history. The immediate priority is emergent management of the DKA with intravenous fluids, insulin, and electrolyte correction. Once the patient is stabilized, the antipsychotic regimen should be reassessed, with strong consideration of switching to a metabolically favorable agent such as aripiprazole, lurasidone, or ziprasidone, since continued olanzapine carries ongoing metabolic risk.
Option A: Option A is incorrect because DKA is a life-threatening emergency, not a benign expected effect; failing to treat it acutely could be fatal.
Option B: Option B is incorrect because olanzapine is well established to impair glucose metabolism; attributing the presentation solely to type 1 diabetes and ignoring the antipsychotic contribution would be a clinical error.
Option D: Option D is incorrect because the patient is on olanzapine, not clozapine, and the presentation is a metabolic emergency (DKA), not clozapine-level toxicity; checking a clozapine level is irrelevant.
Option E: Option E is incorrect because the laboratory picture is metabolic (hyperglycemia, ketoacidosis), not hematologic; agranulocytosis does not produce DKA, and an ANC is not the priority here.
5. A 25-year-old man is brought to the emergency department with acute agitation in the context of a psychotic episode. Twenty minutes ago he received intramuscular lorazepam 2 mg for agitation, with partial effect. The team is now considering intramuscular olanzapine 10 mg to achieve further control. What is the most appropriate course of action with respect to this specific combination?
A) Intramuscular olanzapine should not be co-administered with a parenteral benzodiazepine in the same session because of reported cases of severe respiratory depression and death; the team should avoid giving intramuscular olanzapine now, monitor the patient closely after the lorazepam, and select an alternative approach (for example, allowing time for the lorazepam to act, or using a different agent) if further control is needed
B) Intramuscular olanzapine should be given immediately at a doubled dose to overcome the sedation already produced by lorazepam
C) Intramuscular olanzapine and parenteral benzodiazepines are routinely combined with no safety concern; the team should proceed without additional monitoring
D) Intramuscular olanzapine is contraindicated in all agitated patients regardless of co-medication and should never be used for acute agitation
E) The team should give intravenous olanzapine instead of intramuscular, which eliminates the interaction with parenteral benzodiazepines
ANSWER: A
Rationale:
Intramuscular olanzapine carries a specific safety constraint against co-administration with a parenteral benzodiazepine (intramuscular or intravenous) in the same session, because of reported cases of severe respiratory depression and death. This patient received intramuscular lorazepam 20 minutes ago, so administering intramuscular olanzapine now would create exactly the dangerous overlap the constraint warns against. The appropriate course is to avoid the intramuscular olanzapine at this time, monitor the patient closely after the lorazepam, and choose an alternative strategy if additional control is required.
Option B: Option B is incorrect and dangerous because doubling the olanzapine dose in the setting of a recently administered parenteral benzodiazepine increases, rather than mitigates, the risk of respiratory depression.
Option C: Option C is incorrect because the combination of intramuscular olanzapine with a parenteral benzodiazepine is precisely the combination associated with respiratory depression and death; it is not safe to combine without concern.
Option D: Option D overstates the constraint: intramuscular olanzapine is a legitimate and useful agent for acute agitation; it is not contraindicated in all agitated patients, only constrained against concurrent parenteral benzodiazepine use.
Option E: Option E is incorrect because olanzapine is not administered intravenously for acute agitation, and changing the route would not eliminate the pharmacodynamic additive CNS and respiratory depression risk with a parenteral benzodiazepine.
6. A 78-year-old woman with insomnia and mild anxiety was started by her primary care physician on quetiapine 50 mg at bedtime, used off-label as a sleep aid. She is also taking amlodipine for hypertension. Three days later she reports dizziness on standing and had a witnessed fall when getting up at night, with a documented postural drop in blood pressure. Which mechanism best explains this adverse event, and what is the most appropriate response?
A) The falls are due to quetiapine's antipsychotic dopamine D2 blockade causing parkinsonism; the appropriate response is to add an anticholinergic agent
B) The falls are due to quetiapine-induced agranulocytosis causing weakness; the appropriate response is an urgent absolute neutrophil count
C) The falls are due to quetiapine lowering the seizure threshold; the appropriate response is to add a prophylactic antiepileptic
D) The falls are due to a quetiapine-amlodipine pharmacokinetic interaction at CYP2D6 raising amlodipine levels; the appropriate response is to stop amlodipine
E) The falls are due to alpha-1 adrenergic blockade producing orthostatic hypotension, which is particularly prominent during quetiapine initiation and in elderly patients and those on antihypertensives; the appropriate response is to recognize the orthostatic hypotension, reconsider the off-label use of quetiapine for insomnia given its risk profile, and if continued, titrate slowly from a low starting dose with fall precautions
ANSWER: E
Rationale:
Quetiapine produces orthostatic hypotension through alpha-1 adrenergic blockade, an effect that is particularly prominent during initiation and in elderly patients or those taking antihypertensive agents. This patient has multiple risk factors — advanced age, concurrent amlodipine, and recent quetiapine initiation — and presents with postural dizziness, a documented orthostatic blood pressure drop, and a fall. The appropriate response is to recognize the orthostatic hypotension as the cause, reconsider the off-label use of quetiapine for insomnia given that it carries the agent's full adverse-effect risk at any dose, and, if quetiapine is continued, titrate slowly from a low starting dose with fall precautions. Low-dose quetiapine for sleep is a common but risk-laden off-label practice, especially in older adults.
Option A: Option A is incorrect because at 50 mg quetiapine produces minimal D2 occupancy and parkinsonism is not the mechanism; the presentation is orthostatic, not extrapyramidal, and an anticholinergic would add anticholinergic risk in an elderly patient.
Option B: Option B is incorrect because the presentation is orthostatic hypotension with falls, not a hematologic syndrome; agranulocytosis does not cause postural blood pressure drops, and an ANC is not the priority.
Option C: Option C is incorrect because seizures are not the mechanism of postural dizziness and falls; lowering of the seizure threshold is a clozapine high-dose concern and is not relevant to this low-dose quetiapine orthostatic presentation.
Option D: Option D is incorrect because the mechanism is pharmacodynamic alpha-1 blockade causing orthostasis, not a CYP2D6 interaction; quetiapine is metabolized by CYP3A4, and amlodipine is a CYP3A4 substrate, but the clinical event here is quetiapine-induced orthostatic hypotension, not amlodipine toxicity.
7. A 44-year-old woman with schizophrenia has been well controlled on quetiapine 600 mg per day for two years. She is newly diagnosed with focal epilepsy and started on carbamazepine, a broad inducer of CYP3A4 and other enzymes. Over the next 3 weeks, her psychotic symptoms re-emerge despite full adherence to her unchanged quetiapine dose. Which mechanism best explains the loss of antipsychotic efficacy, and what is the appropriate management?
A) Carbamazepine has inhibited CYP3A4, raising quetiapine levels and causing paradoxical worsening; the appropriate management is to reduce the quetiapine dose
B) Carbamazepine has induced CYP3A4 — quetiapine's primary metabolic enzyme — substantially lowering quetiapine plasma levels (potentially by up to 90%) and rendering the previously effective dose subtherapeutic; the appropriate management is to increase the quetiapine dose substantially (potentially several-fold) if the combination must continue, with a corresponding dose reduction planned if carbamazepine is later stopped
C) Carbamazepine and quetiapine have no pharmacokinetic interaction; the psychotic relapse is coincidental and the quetiapine dose should be left unchanged
D) Carbamazepine has displaced quetiapine from its receptor binding sites; the appropriate management is to switch to a long-acting injectable antipsychotic
E) Carbamazepine has caused quetiapine-induced agranulocytosis, and the relapse reflects systemic illness; the appropriate management is an urgent absolute neutrophil count
ANSWER: B
Rationale:
Quetiapine is metabolized primarily by CYP3A4. Carbamazepine is a potent broad CYP inducer that markedly increases CYP3A4 activity, accelerating quetiapine clearance and lowering its plasma levels — reductions of up to 90% have been described with carbamazepine. The previously effective 600 mg dose becomes subtherapeutic, explaining the re-emergence of psychotic symptoms despite adherence. If the combination must continue, the quetiapine dose must be increased substantially — potentially several-fold — to restore therapeutic levels, with a planned dose reduction if carbamazepine is later discontinued to avoid toxicity from the loss of induction.
Option A: Option A inverts the pharmacology: carbamazepine induces, rather than inhibits, CYP3A4; it lowers quetiapine levels and causes loss of efficacy, so the correct response is a dose increase, not a reduction.
Option C: Option C is incorrect because there is a well-established pharmacokinetic interaction; the relapse is not coincidental, and leaving the dose unchanged would leave the patient subtherapeutic.
Option D: Option D is incorrect because carbamazepine does not displace quetiapine from receptor binding sites; the mechanism is enzyme induction reducing plasma levels, and switching formulation does not address the underlying induction.
Option E: Option E is incorrect because the presentation is loss of antipsychotic efficacy due to a pharmacokinetic interaction, not agranulocytosis; quetiapine does not carry an agranulocytosis risk, and an ANC is not the relevant action.
8. A 24-year-old woman with schizophrenia has been on risperidone 4 mg per day for 14 months. She reports that her menstrual periods stopped about a year ago and that she has noticed milky breast discharge. She is not pregnant. Her clinician is uncertain whether to attribute these symptoms to the antipsychotic, to stress, or to her psychiatric illness. What is the most appropriate diagnostic and management approach?
A) Attribute the symptoms to psychological stress from her illness and provide reassurance without further testing or medication change
B) Increase the risperidone dose, since amenorrhea and galactorrhea indicate inadequate treatment of the underlying psychiatric illness
C) Switch to paliperidone, which shares risperidone's receptor profile, to resolve the symptoms while maintaining equivalent efficacy
D) Check a serum prolactin level; if elevated and other causes are excluded, attribute the hyperprolactinemia to risperidone (the second-generation antipsychotic most associated with sustained prolactin elevation) and consider switching to a prolactin-sparing agent such as aripiprazole or quetiapine, which typically normalizes prolactin within weeks
E) Order a brain MRI to exclude a pituitary tumor as the first and only step, with no consideration of the antipsychotic as the cause
ANSWER: D
Rationale:
Risperidone is the second-generation antipsychotic most reliably associated with sustained, dose-dependent hyperprolactinemia, and amenorrhea with galactorrhea is a classic manifestation. The appropriate approach is to check a serum prolactin level; if it is elevated and other causes are reasonably excluded, the hyperprolactinemia should be attributed to risperidone, and switching to a prolactin-sparing agent (aripiprazole, quetiapine, olanzapine, or clozapine) should be considered. Prolactin typically normalizes within weeks of switching to a prolactin-sparing agent, with resolution of amenorrhea and galactorrhea. Before attributing such symptoms to the psychiatric illness or to other causes, the antipsychotic should be considered as the primary driver.
Option A: Option A is incorrect because attributing the symptoms to stress without checking prolactin or considering the antipsychotic misses the most likely cause — risperidone-induced hyperprolactinemia — and leaves a treatable condition unaddressed.
Option B: Option B is incorrect because prolactin elevation is dose-dependent; increasing the risperidone dose would worsen the hyperprolactinemia, not relieve it.
Option C: Option C is incorrect because paliperidone is the active metabolite of risperidone and produces equivalent hyperprolactinemia; switching to it would not resolve the problem.
Option E: Option E is incorrect because, while a pituitary cause should be considered if prolactin is very high or fails to normalize after stopping the offending drug, ordering an MRI as the first and only step — without checking prolactin or considering the obvious pharmacological cause — is not the most appropriate initial approach.
9. A 38-year-old man with schizophrenia was titrated to risperidone 9 mg per day to achieve symptom control. Over the past 2 weeks he has developed cogwheel rigidity, bradykinesia, and a fine resting tremor, along with restlessness and an inability to sit still (akathisia). His positive symptoms are now reasonably controlled. What is the most appropriate next step in management, and what is the pharmacological rationale?
A) Continue risperidone 9 mg per day and add a long-term anticholinergic agent indefinitely, accepting the extrapyramidal symptoms as an unavoidable cost of efficacy at this dose
B) Increase the risperidone dose further, since extrapyramidal symptoms indicate that the dopamine pathways are not yet adequately blocked
C) Reduce the risperidone dose, because risperidone's extrapyramidal side effects are dose-dependent and emerge as dopamine D2 occupancy crosses the extrapyramidal threshold above approximately 6 to 8 mg per day; doses above 6 mg per day offer diminishing antipsychotic returns with increasing extrapyramidal cost, so dose optimization (rather than indefinite anticholinergic add-on) is the appropriate strategy
D) Switch immediately to a high-potency first-generation antipsychotic such as haloperidol, which produces fewer extrapyramidal symptoms than risperidone
E) Attribute the symptoms to tardive dyskinesia and discontinue all antipsychotic therapy permanently
ANSWER: C
Rationale:
Risperidone's extrapyramidal side effects are distinctly dose-dependent. At doses below approximately 6 to 8 mg per day, risperidone behaves as an atypical agent with low extrapyramidal liability; above that range, dopamine D2 occupancy crosses the extrapyramidal threshold and parkinsonism and akathisia emerge at rates approaching those of high-potency first-generation agents. This patient at 9 mg per day is above the threshold, and doses above 6 mg per day offer diminishing antipsychotic returns while increasing the extrapyramidal cost. The appropriate next step is to reduce the risperidone dose to optimize the balance between efficacy and extrapyramidal burden, rather than committing the patient to an indefinite anticholinergic agent.
Option A: Option A is incorrect because adding a long-term anticholinergic to maintain an unnecessarily high risperidone dose accepts avoidable extrapyramidal symptoms and anticholinergic burden when simple dose reduction would address the root cause.
Option B: Option B is incorrect because increasing the dose would raise D2 occupancy further and worsen the extrapyramidal symptoms; the symptoms reflect excessive, not insufficient, D2 blockade.
Option D: Option D is incorrect because high-potency first-generation agents such as haloperidol produce more, not fewer, extrapyramidal symptoms than risperidone at appropriate doses; this switch would worsen the problem.
Option E: Option E is incorrect because the acute onset of cogwheel rigidity, bradykinesia, resting tremor, and akathisia represents drug-induced parkinsonism and akathisia, not tardive dyskinesia (a late-onset hyperkinetic disorder); abrupt permanent discontinuation of all antipsychotic therapy is not warranted and would risk psychotic relapse.
10. A 31-year-old man with schizophrenia has had three hospitalizations in the past two years, each precipitated by discontinuation of his oral antipsychotic after discharge. When adherent to oral risperidone, he responds well with good symptom control and tolerability. He expresses willingness to try a strategy that does not depend on remembering a daily pill. Which management approach best matches the clinical problem, and what is the supporting rationale?
A) Transition him to a long-acting injectable (LAI) formulation of risperidone or paliperidone, which has the most extensively developed LAI program in the second-generation class — ranging from biweekly risperidone microspheres through monthly, 3-monthly, and 6-monthly paliperidone palmitate — with trial data showing reduced hospitalization and improved adherence outcomes versus oral therapy in patients with documented adherence difficulties
B) Continue oral risperidone and rely on more frequent outpatient appointments to improve adherence, since LAI formulations have not been shown to reduce relapse in any patient population
C) Switch him to clozapine, since recurrent relapse from non-adherence meets the definition of treatment-resistant schizophrenia and mandates clozapine
D) Switch him to oral quetiapine, since its sedating profile will improve adherence by making the patient feel the medication working
E) Discontinue antipsychotic therapy and rely on psychosocial interventions alone, since pharmacological adherence cannot be achieved in this patient
ANSWER: A
Rationale:
This patient's core clinical problem is recurrent relapse driven by non-adherence to oral therapy, in a man who responds well to risperidone when adherent and who is willing to try a non-daily strategy. The best-matched intervention is a long-acting injectable formulation of risperidone or paliperidone. This drug family has the most extensively developed LAI program in the second-generation class — biweekly risperidone microspheres, and monthly, 3-monthly, and 6-monthly paliperidone palmitate formulations — and trial data consistently show reduced hospitalization rates and improved adherence outcomes versus oral formulations in patients with documented adherence difficulties. Switching to an LAI of the agent he already tolerates directly addresses the mechanism of his relapses.
Option B: Option B is incorrect because LAI formulations have demonstrated reduced relapse and hospitalization in patients with adherence difficulties; relying solely on more frequent appointments does not address the fundamental problem as effectively as an LAI.
Option C: Option C is incorrect because relapse driven by non-adherence does not meet the definition of treatment-resistant schizophrenia, which requires failure of two adequate trials at adequate doses in an adherent patient; this patient responds well when adherent, so clozapine is not indicated.
Option D: Option D is incorrect because switching to a sedating oral agent does not solve the adherence problem; the patient still must remember a daily pill, and sedation is not an adherence strategy.
Option E: Option E is incorrect because discontinuing antipsychotic therapy in a patient with relapsing schizophrenia would be harmful; the appropriate response to non-adherence is to use a formulation that does not depend on daily dosing, not to abandon pharmacotherapy.
11. A 47-year-old man with a new diagnosis of schizophrenia has a body mass index of 34, type 2 diabetes mellitus managed with metformin, and dyslipidemia. He has not previously taken an antipsychotic. The treatment team wants to select an initial agent that will control his psychosis while minimizing further metabolic harm. Based on the comparative receptor pharmacology and metabolic profiles of the second-generation antipsychotics, which selection strategy is most appropriate?
A) Start olanzapine, because its robust efficacy outweighs metabolic concerns in any patient regardless of baseline metabolic status
B) Start clozapine first-line, because its superior efficacy makes it the preferred initial agent for all patients with schizophrenia
C) Start high-dose quetiapine, because its metabolic profile is the most favorable of all second-generation agents
D) Avoid all second-generation antipsychotics and use only a high-potency first-generation agent, since second-generation agents uniformly cause severe metabolic harm
E) Start a metabolically favorable second-generation agent such as aripiprazole, lurasidone, or ziprasidone, which have low histamine H1 and serotonin 5-HT2C affinity and correspondingly low weight-gain and glucose-dysregulation liability, making them preferable as initial therapy in a patient with established obesity, diabetes, and dyslipidemia
ANSWER: E
Rationale:
In a patient with established obesity, type 2 diabetes, and dyslipidemia, the priority is to control psychosis while minimizing additional metabolic harm. Aripiprazole, lurasidone, and ziprasidone have low histamine H1 and serotonin 5-HT2C affinity and correspondingly low weight-gain and glucose-dysregulation liability, making them the preferable initial choices in this metabolically vulnerable patient. Matching the agent's metabolic profile to the patient's baseline risk is the appropriate individualized selection strategy emphasized by the comparative effectiveness data.
Option A: Option A is incorrect because olanzapine carries one of the highest metabolic burdens in the class; starting it in a patient with established obesity, diabetes, and dyslipidemia would compound existing metabolic disease and is not appropriate as first-line in this patient.
Option B: Option B is incorrect because clozapine is reserved for treatment-resistant schizophrenia (after two failed trials) and carries the highest metabolic burden plus agranulocytosis risk; it is not a first-line agent for a newly diagnosed patient.
Option C: Option C is incorrect because quetiapine does not have the most favorable metabolic profile; its metabolic burden is intermediate, and at antipsychotic doses it produces meaningful weight gain and glucose effects — it is not the best metabolic choice.
Option D: Option D is incorrect because second-generation agents do not uniformly cause severe metabolic harm; the metabolically favorable agents (aripiprazole, lurasidone, ziprasidone) have low metabolic liability, so avoiding the entire class is unnecessary and would forgo their lower extrapyramidal risk.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.